Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir in relapsing-remitting multiple sclerosis
ISRCTN82487767Phase 2Completed
- Sponsor
- Queen Mary University of London
- Start
- Apr 2013
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of raltegravir in multiple sclerosis (MS), sponsored by Queen Mary University of London. Primary endpoint: Gadolinium-enhanced MRI activity. Started Apr 2013; status: completed.
02
Drugs
raltegravir
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ISRCTN82487767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN82487767.